Nathan J Cherrington, PhD
Biography
Nathan CherringtonĀ is the Associate Dean for Research and Graduate Studies in the College of Pharmacy. He is also the Director of the Southwest Environmental Health Sciences Center and the Interim Director of the Arizona Board of Regents Center for Toxicology. He received a B.S. in Zoology from Brigham Young University and a Ph.D. in Toxicology from North Carolina State University. He then moved to the University of Kansas Medical Center to pursue postdoctoral training in drug metabolism and disposition. He was awarded the Achievement Award by the Society of Toxicology and was made a fellow of the Academy of Toxicological Sciences.
Cancer Focus
Numerous drug-induced toxicities are the result of inter-individual variation in the ADME processes of absorption, distribution, metabolism, and elimination that control the fate of drugs within the body. Alterations in these processes provide the mechanistic basis for individual variability in response to drugs. While there are numerous examples of genetic differences that play a major role in susceptibility, the potential for transient phenotypic conversion due to temporary environmental changes, such as inflammation and disease, are often overlooked. Nonalcoholic Fatty Liver Disease can alter gene expression and function to dramatically alter ADME, resulting in a phenoconversion resembling genetic polymorphisms.
Selected Publications
Miller, S. R., X. Zhang, R. K. Hau, J. L. Jilek, E. Q. Jennings, J. J. Galligan, D. H. Foil, K. M. Zorn, S. Ekins, S. H. Wright, et al., "Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.", Mol Pharmacol, vol. 99, issue 2, pp. 147-162, 2021 02. PMCID: PMC7816041 PMID: 33262250
Miller, S. R., R. K. Hau, J. L. Jilek, M. N. Morales, S. H. Wright, and N. J. Cherrington, "Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2.", Drug Metab Dispos, vol. 48, issue 7, pp. 603-612, 2020 07. PMCID: PMC7318791 PMID: 32393653
Toth, E. L., J. D. Clarke, I. L. Csanaky, and N. J. Cherrington, "Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.", Biochem Pharmacol, vol. 174, pp. 113780, 2020 04. PMCID: PMC7058100 PMID: 31881192
Lake, A. D., R. N. Hardwick, C. P. Leamon, P. S. Low, and N. J. Cherrington, "Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.", Toxicol Appl Pharmacol, vol. 368, pp. 49-54, 2019 04 01. PMCID: PMC6487882 PMID: 30794826
Toth, E. L., H. Li, A. L. Dzierlenga, J. D. Clarke, A. Vildhede, M. Goedken, and N. J. Cherrington, "Gene-by-Environment Interaction of Bcrp and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.", Drug Metab Dispos, vol. 46, issue 11, pp. 1478-1486, 2018 11. PMCID: PMC6193212 PMID: 30166404